Goldman Sachs downgrades Healthways Inc. (hway) to Sell
Goldman Sachs downgrades Healthways Inc. from Neutral to Sell but raises their price target from $9 to $10, which still suggest 31% downside to the current market price.
Goldman Sachs upgraded Johnson & Johnson from Neutral to Buy, while downgrading Bristol-Myers Squibb Co..